The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pai
Completed
- Conditions
- Cancer painCancer
- Registration Number
- ISRCTN17751043
- Lead Sponsor
- Chinese association for the study of pain, the minimally invasive interventional group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
Cancer pain
Exclusion Criteria
1. Researchers think that there is any reason can't include
2. IDDS procedure contraindications
3. Uncooperative and unable to finish the self evaluation (PHQ - 9, GAD - 7 and SF-36)
4. Spinal deformity, intolerance to operation
5. The central infection, severe systemic infection
6. The blood coagulation dysfunction; severe liver and kidney dysfunction
7. Patient who has a history of drug abuse
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Pain after treatment, measured using the visual analogue score (VAS) every day during 3 months after treatment <br>2. Drug cost-effectiveness at 1, 2 and 3 months after treatment
- Secondary Outcome Measures
Name Time Method 1. The frequency, duration and degree of the flare pain everyday during 3 months after treatment<br>2. Intensity of anxiety experienced by patient. measured using the PHQ - 9 evaluation scale at 1, 2 and 3months after treatment<br>3. Intensity of depression experienced by patient, measured by the GAD - 7 anxiety screening scale) at 1, 2 and 3months after treatment<br>4. Quality of life measured by the quality of life score (SF - 36) at 1, 2 and 3 months after treatment